11 completed, 7 unknown, 4 recruiting, 2 withdrawn. 25 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 25 | Completed 11, Unknown 7, Recruiting 4, Withdrawn 2, Terminated 1 |
| Phase 2 | 5 | Completed 4, Unknown 1 |
Follow Acute Heart Failure: new trials by email Literature Review of Acute Heart Failure trials Research Report on Acute Heart Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Role of intraABDOminal Pressure and Point Of Care UltraSound to Guide Decongestive Therapy in Heart Failure Furosemide 20 Milligrams - Acute Heart Failure, Congestive Heart Failure | Phase 3 | Recruiting | Instituto de Investigación Sanitaria Aragón | 168 | 2025-03-10 | 2025-06-06 |
| Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload Acetazolamide, Metolazone 2.5 MG, Double-placebo - Acute Heart Failure | Phase 3 | Recruiting | Johannes Grand | 939 | 2024-09-05 | 2026-10-27 |
| Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure Dapagliflozin 10mg, Acetazolamide 500mg - Acute Heart Failure | Phase 2 / Phase 3 | Completed | Mansoura University | 108 | 2024-08-15 | 2026-10-26 |
| Oxygen Targets in Acute Heart Failure With Pulmonary Congestion Oxygen - Acute Heart Failure, Pulmonary Congestion | Phase 2 / Phase 3 | Completed | Copenhagen University Hospital, Hvidovre | 135 | 2024-02-01 | 2026-10-26 |
| A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients Finerenone, Placebo - Heart Failure, Acute Heart Failure | Phase 3 | Recruiting | Colorado Prevention Center | 5200 | 2024-01-17 | 2026-09-10 |
| Digoxin Short Term Treatment Assessment Randomized Trial in AHF Digoxin, Placebo - Acute Heart Failure | Phase 3 | Completed | University of Monastir | 500 | 2023-05-01 | 2026-10-22 |
| Efficacy and Safety of corticoSTEROids Added to Standard Therapy in Patients With Acute Heart Failure (STERO-AHF) Dexamethasone, Prednisone - Acute Heart Failure | Phase 2 / Phase 3 | Unknown | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 120 | 2023-04-24 | 2023-12-04 |
| Effect of Short-Term Prednisone Therapy on C-Reactive Protein Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers ( CORTAHF ) Prednisone arm, Usual care - Acute Heart Failure | Phase 2 / Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 3 | 2023-02-16 | 2026-01-21 |
| Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction Empagliflozin 10 MG - Acute Heart Failure | Phase 3 | Unknown | Chinese University of Hong Kong | 200 | 2022-09-27 | 2024-02-16 |
| Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure Empagliflozin 10 MG, Placebo - Acute Heart Failure | Phase 3 | Recruiting | Juntendo University | 444 | 2022-09-10 | 2026-02-13 |
| Canagliflozin in Patients With Acute Decompansted Heart Failure Canagliflozin, Empagliflozin - Chronic Heart Failure, Acute Heart Failure | Phase 3 | Completed | October 6 University | 142 | 2022-06-04 | 2024-07-11 |
| Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF) Dapagliflozin 10mg Tab, Placebo - Acute Heart Failure | Phase 2 / Phase 3 | Completed | Mansoura University | 87 | 2022-04-25 | 2023-08-04 |
| Sodium Chloride vs. Glucose Solute as a Volume Replacement Therapy During Decongestion in Acute Heart Failure Furosemide intravenous infusion, Continous intravenous infusion of 0.9% Sodium Chloride solution, Continous intravenous infusion of 5% Glucose solution - Acute Heart Failure, Congestion | Phase 3 | Completed | Wroclaw Medical University | 50 | 2022-02-01 | 2024-06-21 |
| Exogenous Ketones for Acutely Decompensated HEart Failure 25g Ketone monoester without added salts, Placebo - Acute Heart Failure, Low Cardiac Output Syndrome | Phase 3 | Unknown | Institute for Clinical and Experimental Medicine | 24 | 2020-12-02 | 2021-01-06 |
| Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study Spironolactone or hydrochlorothiazide, Placebo - Acute Heart Failure, Acute Kidney Injury | Phase 3 | Unknown | Chiang Mai University | 100 | 2020-08-13 | 2020-08-18 |
| Sequential Nephron Blockade in Acute Heart Failure Metolazone, Loop Diuretics - Acute Heart Failure | Phase 3 | Unknown | Policlinico Casilino ASL RMB | 310 | 2019-10-01 | 2019-11-19 |
| Acetazolamide in Patients With Acute Heart Failure Acetazolamide, Placebo - Heart Failure, Acute Heart Failure | Phase 3 | Unknown | University of Sao Paulo General Hospital | 90 | 2018-10-01 | 2018-10-30 |
| Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label) - Dyspnea, Hypertension | Phase 3 | Withdrawn | The Medicines Company | 2014-08-01 | 2020-10-19 | |
| Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF Serelaxin, Placebo, Standard of CareTherapy - Acute Heart Failure | Phase 3 | Terminated | Novartis Pharmaceuticals | 876 | 2014-03-12 | 2019-08-02 |
| Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF RLX030, Placebo - Acute Heart Failure | Phase 3 | Completed | Novartis Pharmaceuticals | 6600 | 2013-10-02 | 2018-03-30 |
Showing 20 of 25. Sign in to see all of them.
Heart Failure (4) · Emergencies (2) · Acute Kidney Injury (1) · Cardiac Output, Low (1) · Cardio-Renal Syndrome (1) · Diabetes Insipidus (1) · Diabetes Mellitus (1) · Dyspnea (1) · Hypertension (1) · Hypoxia (1) · Inflammation (1) · Intra-Abdominal Hypertension (1) · Ketosis (1) · Pulmonary Edema (1) · Ventricular Dysfunction, Left (1)
Cardiovascular Diseases (7) · Heart Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Kidney Diseases (3) · Male Urogenital Diseases (3) · Pathologic Processes (3) · Signs and Symptoms (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Disease Attributes (2) · Endocrine System Diseases (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2)
Acetazolamide (3) · empagliflozin (3) · Metolazone (2) · dapagliflozin (2) · tezosentan (2) · Canagliflozin (1) · Dexamethasone (1) · Digoxin (1) · Dobutamine (1) · Double-Blind Method (1) · Hydralazine (1) · Hydrochlorothiazide (1) · Isosorbide Dinitrate (1) · Oxygen (1) · Prednisone (1)
Idorsia Pharmaceuticals Ltd. (2) · Mansoura University (2) · Novartis Pharmaceuticals (2) · Abbott (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Chiang Mai University (1) · Chinese University of Hong Kong (1) · Colorado Prevention Center (1) · Copenhagen University Hospital, Hvidovre (1) · Institute for Clinical and Experimental Medicine (1) · Instituto de Investigación Sanitaria Aragón (1) · Johannes Grand (1) · Juntendo University (1) · Maisel, Alan, M.D. (1)
United States (6) · Italy (5) · Czechia (4) · Denmark (4) · Germany (4) · Poland (4) · United Kingdom (4) · Australia (3) · Brazil (3) · Egypt (3) · France (3) · Greece (3) · Hungary (3) · Spain (3) · Argentina (2)
Moheb Magdy Mouris, MD (2) · Noha Mansour, PhD (2) · Alan S Maisel, MD (1) · Bryan Yan (1) · Gad Cotter, MD (1) · Gennaro Cice, MD (1) · Ida Taraldsen, MD (1) · Jens Hove, MD, PhD (1) · Johannes Grand, MD, PhD (1) · Johannes Grand, MD, Phd, MPH (1) · Kajohnsak Noppakun, MD (1) · Karen Sliwa, PhD (1) · Mohamed El- Husseiny Shams, Professor (1) · Mohamed El-Husseiny Shams, Proffesor (1)
PMID 17986694, PMID 26721775, PMID 34514815, PMID 35184572, PMID 17473298, PMID 19539144, PMID 27206810, PMID 28452195, PMID 31433919, PMID 33189635, PMID 33247624, PMID 34627724, PMID 37923161, PMID 39614837, PMID 40455066, PMID 40845614, PMID 40902819